How To Stay Focused At Work When Everything Feels Uncertain https://t.co/ktH3GaErxD https://t.co/ktH3GaErxD ...

Tim Spence, chairman, CEO & president of Fifth Third Bank, joins "Open Interest" to discuss the impact stablecoin technology will have on the bank's operations. Congress delivered a watershed victory for the crypto industry last Thursday, passing the first federal legislation to regulate stablecoins and clearing the way for broader use of the technology in everyday finance http://bloom.bg/3GNlHBZ ...

Key Takeaways Block jumped 24.7% in a month, outperforming its industry's 5.7% gain and rising 7.2% intraday yesterday. SBlock, Inc. (XYZ) shares have surged 24.7% in a month, outperforming its industry’s rise of 5.7%. Notably, XYZ shares gained 7.2% during the intra-day trading session yesterday, after Block had made it to the coveted S&P 500 list.On Friday, July 18, S&P Dow Jones Indices announced that it will add Block to the S&P 500 Index, replacing Hess, which is set to be acquired by Chevron. The cha ...

主要为中小型生物技术公司提供临床研发外包服务的美国合同研究组织（CRO）Medpace刚刚公布的财报业绩强劲，股价大 涨。 EBITDA：二季度息税折旧摊销前利润（EBITDA）为1.305亿美元，同比增长16.2%，EBITDA利润率为21.6%，一 季度EBITDA同比增长2.6%、EBITDA利润率为21.2%。 2）业绩指引： 美东时间7月22日周二，Medpace股价（MEDP）跳空高开逾44%，早盘涨幅一度扩大到62.3%，后涨幅有所收窄，早盘尾声时 涨超50%，势将创收盘最高纪录，并创上市将近九年来最大单日涨幅。 Medpace股价暴涨也带飞了CRO概念股。周二美股早盘尾声时，Iqvia Holdings（IQV）涨近20%，ICLR PLC（ICLR）涨超 10%，Charles River Laboratories International（CRL）早盘曾涨超10%。 股价大涨前，本周一美股盘后，Medpace公布截至6月30日的公司第二季度财务业绩，并能提供以及2025年全年的业绩指引。 1）主要财务数据： 营收：二季度营收6.033亿美元，同比增长14.2%，分析师预期5.42亿美元， ...

Summary of Oncolytics Biotech Key Opinion Leader Webinar Company and Industry - **Company**: Oncolytics Biotech - **Industry**: Oncology, specifically focusing on pancreatic cancer and other gastrointestinal cancers Core Points and Arguments 1. **Introduction of Pelareorep**: Pelareorep is an oncolytic virus that selectively targets cancer cells and is administered intravenously, making it easier for widespread application compared to other oncolytic viruses that require intratumoral administration [6][7][8] 2. **Efficacy in Pancreatic Cancer**: Pelareorep has shown strong efficacy signals in pancreatic cancer, with a 62% overall response rate observed in clinical studies, which is significantly higher than traditional chemotherapy combinations [15][34] 3. **Unmet Need in Pancreatic Cancer**: Pancreatic cancer is the 10th most common cancer but the second leading cause of cancer death, highlighting the urgent need for effective treatments [10][11] 4. **Current Treatment Landscape**: Standard treatments include gemcitabine and FOLFIRINOX, with limited overall survival rates. Pelareorep combined with chemotherapy has shown improved survival rates compared to historical controls [12][13][22] 5. **Safety Profile**: Over 1,100 patients have been treated with Pelareorep, showing a favorable safety profile with mild side effects such as flu-like symptoms, indicating it is well-tolerated [66][70] 6. **Combination Therapy Potential**: Pelareorep can be combined with various chemotherapy regimens and checkpoint inhibitors, enhancing its therapeutic potential across multiple cancer types [86] 7. **Goblet Trial**: The Goblet trial is a significant study evaluating Pelareorep in combination with gemcitabine, nab-paclitaxel, and atezolizumab, showing promising early results [34][35] 8. **Biomarker Insights**: Tumor-infiltrating lymphocyte expansion has been identified as a potential biomarker correlating with treatment response, suggesting a mechanism of action that enhances immune response [40][41] Other Important but Possibly Overlooked Content 1. **Durability of Response**: The durability of responses in patients treated with Pelareorep is a notable characteristic, indicating potential long-term benefits [15] 2. **Mechanism of Action**: Pelareorep induces endoplasmic reticulum stress in pancreatic cancer cells, leading to apoptosis, which supports its mechanism of action [20] 3. **Future Directions**: There is a strong interest in exploring Pelareorep in registration-enabling studies for first-line treatment in pancreatic cancer, given the promising efficacy and safety data [57][69] 4. **Cross-Tumor Potential**: Pelareorep has demonstrated efficacy across various tumor types, including breast and colorectal cancers, indicating its potential as a versatile therapeutic agent [86] This summary encapsulates the key insights and discussions from the Oncolytics Biotech webinar, focusing on the promising role of Pelareorep in treating pancreatic cancer and its potential applications in other cancers.

Bedrock Robotics, led by a veteran of Alphabet Inc.’s autonomous tech unit, is emerging from stealth with $80 million and plans to make heavy construction equipment work around-the-clock without human operators.Read more: https://t.co/bGXtPA58JA https://t.co/VCQz1oo3Hl ...

So Jack, um, real short-term tactical stuff here. You did see this fade in the indexes here. We're at highs, you know, for for the major indexes.The atmospheric conditions seem pretty favorable here. What's your read on on what we're seeing. Yeah, I mean, I think right now it's a pretty quiet data, pretty quiet week from a data perspective.There aren't a lot of policy headlines hitting us, at least not expected to this week. You know, all markets can really focus in on is this earning season. And the earnin ...

Core Viewpoint - The European Commission is likely to accept Apple's proposed changes to its App Store rules and fees, which would eliminate the risk of daily fines from the antitrust regulator [1][2]. Group 1: Regulatory Context - The European Commission ruled in April that Apple violated the Digital Markets Act (DMA) by preventing app developers from promoting cheaper deals outside of its App Store, resulting in a fine of 500 million euros (approximately $587 million) [3]. - Apple was given 60 days to modify its policies to comply with the DMA following the ruling [3]. Group 2: Proposed Changes by Apple - Apple announced in June that it would implement changes allowing developers to pay a 20% processing fee for purchases made in the App Store and a 5% to 15% fee for directing customers to external payment options [4]. - The changes would also permit developers to provide links to alternative payment methods [4]. Group 3: Potential Consequences - If the European Commission had rejected Apple's changes, it could have imposed daily fines amounting to 5% of Apple's average daily worldwide revenue [4]. - Apple has previously expressed that the European Commission's actions are unfair and detrimental to user privacy and security, and it has appealed the fine, claiming it is unlawful [5].

RT Sawyer Merritt (@SawyerMerritt)Tesla's Diner uses higher-quality ingredients than most fast food burger chains.• Fries are cooked in beef tallow• Breakfast items have organic eggs from pasture-raised chickens fed with all-vegetable grains• The Kombucha uses 100% raw, organic ingredients• The yogurt & milk they use is organic• Bacon uses heritage-bred pork• Flour tortillas are made with heritage organic wheat• The cheese has no phosphates, starches, acids, or fillersThe vast majority of the ingredients ar ...

Hey everyone and thanks for jumping back into the cryptoverse. Today we're going to talk about constructing a cryptocurrency portfolio and how to do so if say you're investing $1,000 into crypto. If you guys like the content, make sure you subscribe to the channel, give the video a thumbs up, and also check out the sale on into the cryptoverse premium at into the cryptoverse.com. Let's go ahead and jump in. So, we do this video about every 6 months, right? There's actually a playlist if you're interested. T ...